ENGENE
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
ENGENE
Social Links:
Industry:
Biotechnology Diabetes Genetics Health Care
Founded:
1999-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.engene.com
Total Employee:
51+
Status:
Active
Contact:
604-221-4362
Email Addresses:
[email protected]
Total Funding:
33.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Content Delivery Network Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail ReCAPTCHA
Similar Organizations
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - enGene
Lumira Ventures
Lumira Ventures investment in Venture Round - enGene
Forbion Capital Partners
Forbion Capital Partners investment in Series B - enGene
Lumira Ventures
Lumira Ventures investment in Series B - enGene
Inbio Ventures
Inbio Ventures investment in Series B - enGene
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - enGene
Pharmstandard
Pharmstandard investment in Series B - enGene
Lumira Ventures
Lumira Ventures investment in Venture Round - enGene
RBC Capital Markets
RBC Capital Markets investment in Series A - enGene
Adams, Harkness & Hill Technology Ventures
Adams, Harkness & Hill Technology Ventures investment in Series A - enGene
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-17 | enGene Appoints James C. Sullivan, PhD as Chief Scientific Officer |
Official Site Inspections
http://www.engene.com Semrush global rank: 7.57 M Semrush visits lastest month: 458
- Host name: 79.1.212.35.bc.googleusercontent.com
- IP address: 35.212.1.79
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "enGene"
enGene - Crunchbase Company Profile & Funding
EnGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery …See details»
enGene - About Us - Boldly Focused on Patient Needs
The passionate experts at enGene have extensive experience in drug development and commercialization. We are boldly focused on patient needs.See details»
enGene - Overview, News & Similar companies | ZoomInfo.com
EnGene Reports Second Quarter 2024 Financial Results and Provides a Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, …See details»
enGene - LinkedIn
EnGene | 11,565 followers on LinkedIn. On a mission to mainstream genetic medicines through delivery of therapeutics to mucosal tissues & other organs | At enGene, we are at the …See details»
enGene Inc. - Montreal, Canada - bionity.com
Jan 28, 2015 enGene Inc. is a private Canadian biotechnology company developing an innovative mucosal immunotherapy platform for treating several prevalent, chronic diseases …See details»
enGene - VentureRadar
EnGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan …See details»
enGene - Products, Competitors, Financials, Employees, …
About enGene. enGene is a biotechnology company focused on developing non-viral gene therapies for underserved diseases. The company's main offerings include a novel gene …See details»
enGene Holdings Inc. (ENGN) Company Profile & Overview - Stock …
Nov 21, 2024 enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of …See details»
enGene Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 enGene has 2 employees across 2 locations. See insights on enGene including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
enGene - Funding, Financials, Valuation & Investors - Crunchbase
EnGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins. Search Crunchbase. ... How much funding has this …See details»
enGene Holdings Inc. (ENGN) - Yahoo Finance Canada
EnGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics …See details»
Investors - enGene
Stay informed about enGene by viewing our company press releases, events, SEC filings, and corporate and scientific presentations.See details»
A Brief History of enGene - CBM
Oct 2, 2024 [cbm_blg_rlnkng]EnGene is a revolutionary biotechnology company that has been making waves in the field of gene therapy since its inception in 2014. Founded by a team of …See details»
enGene Announces Appointment of Ron Cooper as Chief …
BOSTON & MONTREAL, July 24, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead …See details»
enGene Announces Appointment of Ron Cooper as Chief …
Jul 24, 2024 BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead …See details»
EnGene - adMare Bio
EnGene is leader in nucleotide delivery to the intestine. The company has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat …See details»
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic
Nov 1, 2023 The boards of directors of enGene and enGene Inc. also unanimously approved the business combination, and enGene Inc.'s shareholders voted in favor of the business …See details»
enGene Reports Full Year 2023 Financial Results and Recent …
BOSTON and MONTREAL, Jan. 29, 2024 /CNW/ – enGene Holdings Inc. (Nasdaq: ENGN) (or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead …See details»
enGene - Presentations
Stay informed about enGene by viewing our company press releases, events, SEC filings, and corporate and scientific presentations.See details»